Neuroimmunology Drug Development
|出版日||ページ情報||英文 76 Pages
当レポートでは、世界の免疫神経薬市場における新製品の治験・開発動向について分析し、免疫神経製品の定義・分類方法や共通標的、現在の治験の進行状況 - 疾患別・フェーズ別・地域別など -、最大手企業10社の概略と主力製品、今後の技術・市場動向に対する専門家の見解、といった情報を取りまとめてお届けいたします。
Among the different molecule types in neuroimmunology, mAbs and small molecules are the most common. This is primarily due to the specificity of the former and the ability of the latter to penetrate the BBB. However, the cost factor associated with mAbs-based therapy is seen as a hurdle for wider market acceptances.
Neuroimmunology is expected to be an area that will witness strong growth in the future due to a number of factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer's disease (AD) and Multiple Sclerosis (MS).
The most common targets adopted by pipeline drugs for MS include cytokines or cytokine receptors, as well as lymphocytes or molecule s associated with their activation or migration. The majority of pipeline drugs for AD are aimed at targeting the AB protein, the historical results of which have not been strong enough to be assigned as a breakthrough therapy.
The KOLs interviewed have highlighted the high cost of therapy associated with a mAb based therapy which is perceived as a hurdle for such drugs to be widely accepted in the market; this factor is expected to lead companies to develop more cost-efficient therapies based on alternate molecule types. They've also expressed the need for long-term safety and clinical data, as well as data to help them with decisions on sequential or combination therapies in neuroimmunology. These challenges are compounded when rare diseases are considered, primarily those related to patient recruitment.
The "Neuroimmunology Drug Development", report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. This report provides an overview of current clinical and product development trends for neuroimmunology within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current pipeline drugs, focus on product development in indications such as AD and MS, and unmet needs within neuroimmunology.
This report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. Components of the slide deck include primary and secondary research -